查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2004998

豬疫苗市場：依疫苗類型、目標疾病、最終用戶、給藥途徑、技術和劑型分類－2026-2032年全球市場預測

Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route Of Administration, Technology, Dosage Form - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，豬疫苗市場價值將達到 19.4 億美元，到 2026 年將成長到 20.7 億美元，到 2032 年將達到 31.2 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 19.4億美元
預計年份：2026年 20.7億美元
預測年份：2032年 31.2億美元
複合年成長率 (%) 6.99%

一篇清晰權威的介紹，說明了近期科學、監管和運營方面的變化如何重新定義豬疫苗研發的優先事項。

豬隻疫苗領域正處於轉型期，其驅動力來自於技術創新、生產方法的改進以及養殖場需求的轉變。核酸技術的進步、佐劑配方的最佳化以及給藥途徑的改進，都改變了人們對產品性能的預期以及研發流程。同時，監管機構也正在更新新平台和生產品質框架的指導意見，這要求研發人員和生產商能夠更靈活地調整其臨床開發計畫和生產控制措施。

平台創新、監測數據和以現場為中心的管理方法如何推動您的豬隻疫苗策略發生系統性轉變？

隨著平台技術和疾病標靶策略的日益成熟，豬隻免疫的前景正從漸進式產品改進轉向結構性變革。基於RNA的療法、重組表達系統和病毒載體，結合佐劑和製劑技術的進步，正在加速抗原發現並實現更靈活的生產。這些技術的整合縮短了從病原體鑑定到候選疫苗部署的時間，改變了企業規劃產品線和分配研發資源的方式。

對 2025 年美國實施的關稅變化對營運鍊和採購的影響進行全面分析。

美國2025年宣布的關稅政策調整對豬隻疫苗相關相關人員的採購、供應鏈經濟和戰略採購產生了多方面的影響。某些生技藥品原料和部分生產耗材的關稅上調，推高了依賴國際原料供應的供應商的投入成本，進而影響了製造商和合約服務供應商的定價策略和供應商選擇。為此，許多機構審查了其供應商基礎，並加快了對替代性國內或區域供應商的認證，以降低關稅變化帶來的風險。

將疫苗平台、目標疾病、最終用戶需求、給藥途徑、製造技術和劑型與策略重點連結起來的綜合細分分析。

一個精細的細分框架揭示了產品開發、部署策略和最終用戶接受度如何因疫苗類型、適應症、最終用戶、給藥途徑、技術和劑型而異。去活化疫苗、減毒活病毒疫苗、mRNA疫苗、次單位疫苗和病毒載體疫苗之間的差異會影響研發進度和監管考量。例如，去活化疫苗可進一步分為裂解病毒製劑、亞細胞製劑和全病毒製劑，而減毒活病毒疫苗則根據其異質設計和同質設計進行區分。 mRNA製劑需要根據其是否擴增或自擴增而進行不同的最佳化，而次單位疫苗則必須在多醣亞次單元策略和蛋白質次單元策略之間做出選擇。病毒載體平台可以利用腺病毒或痘病毒載體骨架，每種載體在免疫學和生產方面都有不同的權衡取捨。

美洲、歐洲、中東和非洲以及亞太地區的區域策略挑戰將決定豬疫苗的監管、分銷和部署管道。

區域趨勢對塑造研究重點、監管策略和商業化途徑至關重要。美洲呈現出一個異質性生態系統，大規模商業運營和先進的獸醫服務網路推動了對複雜平台解決方案和精準免疫策略的需求，而監管重點則放在生產品質和核准後監測上。相較之下，歐洲、中東和非洲的法規結構和基礎設施差異顯著，需要靈活的商業化模式，以適應高度監管的市場以及低溫運輸和獸醫服務能力有限的地區。亞太地區由於特定區域創新技術的快速應用，以及中東和非洲小規模農業人口的廣泛分佈，需要採取類似的策略，在應用高科技平台的同時，兼顧成本效益高、適合田間實際情況的疫苗選擇。

創新主導研發公司、契約製造和策略夥伴如何為豬疫苗的整個價值鏈創造競爭優勢？

競爭格局呈現出多元化的特點，既有成熟的動物用藥品公司，也有專注於生物技術創新的企業、合約契約製造機構（CDMO）和學術研究中心。領先的研發公司正優先考慮平台多元化，以平衡短期商業產品和長期臨床實驗候選藥物，並經常尋求能夠將臨床開發優勢與可擴展生產技術相結合的夥伴關係關係。契約製造製造商和CDMO的角色日益重要，它們使中小創新企業能夠利用符合GMP標準的生產系統，並使大型企業能夠在避免固定資產過度投資的同時，柔軟性管理其生產能力。

為開發人員和相關人員提供極具影響力和可操作性的策略建議，以加速豬疫苗領域的平台準備、供應彈性和最終用戶採用。

產業領導者應採取三支柱策略方針，將科學知識與業務永續營運和精簡的市場准入相結合。首先，優先投資兼具彈性和廣度的平台。例如，在維持最佳化傳統產品線的同時，擴展RNA和重組技術能力，既能快速應對新出現的威脅，又能穩定地提供針對地方性疾病的產品。其次，透過認證取代原料、投資區域生產或填充和包裝能力，以及加強低溫運輸基礎設施，建構供應鏈韌性，從而降低因貿易中斷和關稅導致的成本轉移而帶來的風險。

嚴謹的多面向調查方法，包括與專家的初步訪談、監管審查、科學文獻整合以及基於情境的供應鏈分析。

本研究整合了從科學文獻、監管指導文件、行業資訊披露、技術簡報以及與價值鏈各環節專家的訪談中獲得的定性和定量資訊。研究優先考慮了平台免疫學和藥物科學的同行評審研究、與生技藥品和新型療法相關的監管指南以及來自生產和分銷相關人員的營運文件，從而全面觀點了技術、供應和應用趨勢。

結論強調整合是未來豬隻疫苗接種發展的基礎，重點在於技術融合、供應彈性和協作方法。

豬疫苗生態系統正日益受到技術創新、務實考量和不斷變化的政策環境三者相互作用的影響。平台技術的進步為擴大預防範圍和提高反應速度提供了切實機遇，但要實現這些優勢，需要對生產柔軟性、監管策略和現場供給能力進行協調一致的投資。同時，貿易政策的變化和供應鏈壓力凸顯了區域多元化和供應商合格對於確保供應連續性和控制成本風險的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：豬疫苗市場：依疫苗類型分類

  • 失活
    • 分裂病毒
    • 細胞內成分
    • 所有病毒
  • 減毒活病毒疫苗
    • 不同物種
    • 同種
  • mRNA
    • 未擴增的mRNA
    • 自擴增mRNA
  • 次單元
    • 多醣體次單元
    • 蛋白質次單元
  • 病毒載體類型
    • 腺病毒載體
    • 痘病毒載體

第9章：豬疫苗市場：依目標疾病分類

  • 經典豬瘟
  • 豬丹毒
  • 豬繁殖與呼吸綜合症
  • 豬流感

第10章：豬疫苗市場：依最終用戶分類

  • 商業農場
  • 研究機構
  • 小農戶
  • 動物醫院

第11章：豬隻疫苗市場：依給藥途徑分類

  • 皮內注射
  • 肌肉內部
  • 鼻內
  • 口服
  • 皮下

第12章：豬疫苗市場：依技術分類

  • 傳統的
    • 減毒活病毒疫苗
    • 去活化全抗原
  • DNA
  • 重組
    • 細菌表達
    • 昆蟲細胞表達
    • 酵母表達
  • RNA
  • VLP

第13章：豬疫苗市場：以劑型分類

  • 乳液
  • 液體
  • 冷凍乾燥

第14章：豬疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：豬疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 豬疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國豬疫苗市場

第18章：中國豬疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bimeda Holdings PLC
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Chengdu Tianbang Biological Products Co., Ltd.
  • Chopper Animal Health Co., Ltd.
  • Elanco Animal Health Incorporated
  • Hipra, SA
  • Indian Immunologicals Ltd.
  • Jinyu Bio-Technology Co., Ltd.
  • Kyoritsu Seiyaku Corporation
  • Merck & Co., Inc.
  • Pharmgate Animal Health, LLC
  • Phibro Animal Health Corporation
  • Qilu Animal Health Products Co., Ltd.
  • Vaxxinova International BV
  • Venkateshwara Hatcheries Pvt. Ltd.
  • Zoetis Inc.
Product Code: MRR-742BD5183CF6

The Porcine Vaccines Market was valued at USD 1.94 billion in 2025 and is projected to grow to USD 2.07 billion in 2026, with a CAGR of 6.99%, reaching USD 3.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.94 billion
Estimated Year [2026] USD 2.07 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 6.99%

A clear, authoritative primer explaining how recent scientific, regulatory, and operational changes are redefining priorities in porcine vaccine development

The porcine vaccine arena stands at an inflection point driven by converging scientific innovation, evolving production modalities, and shifting farm-level needs. Advances in nucleic acid technologies, improved adjuvant formulations, and more refined delivery routes have altered both product performance expectations and development pathways. Meanwhile, regulatory authorities are updating guidance on novel platforms and manufacturing quality frameworks, which requires developers and producers to adapt clinical development plans and manufacturing controls with greater agility.

Operational pressures across supply chains and the increasing focus on biosafety and traceability are reshaping procurement practices among commercial farms, veterinary hospitals, and research institutes. As stakeholders prioritize resilience and predictability, there is a growing premium on vaccines that combine robust efficacy profiles with simplified administration and storage requirements. Collectively, these dynamics are redefining investment priorities, strategic partnerships, and pipeline development across the sector.

How converging platform innovations, surveillance intelligence, and field-centric delivery approaches are driving systemic transformation in porcine vaccine strategies

The landscape for porcine immunization is moving from incremental product improvement toward structural transformation as platform technologies and disease targeting strategies mature. RNA-based modalities, recombinant expression systems, and viral vectors are converging with improved adjuvant and formulation science to enable faster antigen discovery and adaptable manufacturing. This technological convergence shortens the interval between pathogen identification and candidate deployment, thereby changing how companies plan pipelines and allocate R&D resources.

Concurrently, disease surveillance networks and data integration across farms and veterinary services are enabling earlier outbreak detection and more precise vaccine deployment strategies. These capabilities are encouraging stakeholders to invest in modular production capacity, cold chain innovations, and alternative routes of administration that reduce labor and stress at the herd level. As a result, strategic emphasis is shifting toward platform flexibility, cross-protection potential, and ease of field use, which together are driving new collaboration models between developers, contract manufacturers, and end users.

Comprehensive analysis of the cascading operational and sourcing consequences that resulted from the United States tariff changes implemented in 2025

US tariff policy changes announced in 2025 have had multifaceted implications across sourcing, supply chain economics, and strategic procurement for porcine vaccine stakeholders. Increased duties on selected biologics inputs and certain manufacturing consumables elevated input costs for suppliers that rely on international raw material flows, which in turn influenced pricing strategies and vendor selection for manufacturers and contract service providers. In response, many organizations reassessed supplier footprints and accelerated qualification of alternative domestic or regional suppliers to reduce exposure to tariff variability.

These adjustments also pushed manufacturers to evaluate inventory policies and to strengthen contractual terms with upstream suppliers to secure supply continuity. For end users such as commercial farms and veterinary networks, procurement practices evolved toward longer-term purchasing agreements and collaborative planning to smooth supply disruptions. Policymakers and industry groups engaged in dialogue to clarify tariff scope and to explore mitigations, including targeted exemptions, streamlined customs processes, and incentives for local production capacity to reinforce resilience and hedging against future trade volatility.

An integrated segmentation analysis linking vaccine platforms, disease targets, end-user needs, administration routes, production technologies, and dosage formats to strategic priorities

A nuanced segmentation framework reveals how product development, deployment strategies, and end-user uptake diverge across vaccine type, disease indication, end user, route of administration, technology, and dosage form. Vaccine type distinctions between Inactivated formats, Live Attenuated preparations, mRNA constructs, Subunit vaccines, and Virus Vectored solutions shape development timelines and regulatory considerations; for example, Inactivated vaccines vary further as Split Virus, Subcellular, and Whole Virus formulations, while Live Attenuated approaches are differentiated by Heterologous and Homologous design choices. mRNA modalities require different optimization depending on whether they are Non-Amplifying or Self-Amplifying constructs, and Subunit vaccines call for choices between Polysaccharide Subunit and Protein Subunit strategies. Virus Vectored platforms may leverage Adenovirus Vector or Poxvirus Vector backbones, each with distinct immunologic and manufacturing trade-offs.

Disease indication segmentation including Classical Swine Fever, Erysipelas, Porcine Reproductive And Respiratory Syndrome, and Swine Influenza directs antigen selection priorities and field trial design. End users such as Commercial Farms, Research Institutes, Smallholder Farms, and Veterinary Hospitals present contrasting adoption criteria that influence dosing regimens, packaging, and service models. Route of administration choices spanning Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous determine product format and on-farm labor implications. Underlying technology categories of Conventional, DNA, Recombinant, RNA, and VLP further shape development pathways, with Conventional pathways subdividing into Attenuated Live and Killed Whole approaches and Recombinant strategies differentiating between Bacteria Expressed, Insect Cell Expressed, and Yeast Expressed production methods. Dosage form variants across Emulsion, Liquid, and Lyophilized formats affect logistics and shelf-life considerations. Taken together, this segmentation matrix clarifies where technical investment and commercialization focus will yield the greatest operational and clinical impact.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine regulatory, distribution, and adoption pathways for porcine vaccines

Regional dynamics are critical for shaping research priorities, regulatory strategy, and commercialization approaches. The Americas present a heterogeneous ecosystem in which large commercial operations and sophisticated veterinary service networks drive demand for advanced platform solutions and precision immunization strategies, while regulatory scrutiny emphasizes manufacturing quality and post-licensure surveillance. In contrast, Europe, Middle East & Africa exhibits wide variability across regulatory frameworks and infrastructure, requiring adaptable commercialization models that can accommodate both highly regulated markets and areas with more constrained cold chain or veterinary services capacity. Asia-Pacific combines rapid innovation adoption in certain hubs with extensive smallholder populations in other geographies, necessitating a dual-track approach that balances high-tech platform deployment alongside cost-effective, field-friendly vaccine options.

These regional contrasts influence R&D prioritization, partnership models, and distribution strategies. For developers and suppliers, success depends on tailoring dossiers and evidence packages to regulatory expectations in each region while designing logistics and service models that match local end-user capabilities. Consequently, strategic regional investments in manufacturing, cold chain enhancements, and localized training programs can materially affect uptake and long-term adoption trajectories across geographies.

How innovation-led developers, contract manufacturers, and strategic collaborations are shaping competitive differentiation across the porcine vaccine value chain

The competitive landscape is characterized by a mix of established animal health corporations, specialized biotech innovators, contract manufacturing organizations, and academic research centers. Leading developers emphasize platform diversification to balance near-term commercial products with longer-term investigational candidates, often pursuing partnerships that combine clinical development strength with scalable manufacturing expertise. Contract manufacturers and CDMOs are playing an increasingly pivotal role, enabling smaller innovators to access GMP-compliant production and allowing larger firms to manage capacity flexibility without over-investing in fixed assets.

Strategic behaviors among companies include vertical integration of supply chains, targeted acquisitions to close capability gaps in novel platforms, and collaborative research agreements that accelerate antigen discovery and immunogenicity testing. Firms that invest in robust regulatory affairs teams and post-approval surveillance capabilities achieve smoother product rollouts and stronger stakeholder trust. Meanwhile, companies prioritizing field-centric design-such as simplified dosing regimens, thermostable formulations, and minimally invasive delivery-are better positioned to capture adoption among diverse end users. Overall, sustained competitive advantage arises from the intersection of scientific excellence, manufacturing resilience, and deep understanding of end-user operational needs.

High-impact, practical strategic recommendations for developers and stakeholders to accelerate platform readiness, supply resilience, and end-user adoption in the porcine vaccine sector

Industry leaders should adopt a three-pronged strategic approach that aligns scientific capability with operational resilience and market access facilitation. First, prioritize platform investments that deliver both agility and breadth; for example, expanding RNA and recombinant capabilities while maintaining optimized conventional pipelines can enable both rapid response to emergent threats and stable product offerings for endemic diseases. Second, build supply chain resilience by qualifying alternative raw material sources, investing in regional production or fill-finish capacity, and enhancing cold chain infrastructure to reduce vulnerability to trade disruptions and tariff-induced cost shifts.

Third, strengthen end-user engagement by co-developing administration and training programs with veterinary networks and farm groups so that product attributes are matched to field realities. In parallel, pursue regulatory engagement early in development to align on evidence requirements for novel platforms and to expedite approval pathways. Finally, consider flexible commercial models such as subscription-style supply agreements or tiered pricing to expand reach across different end-user segments while maintaining sustainable revenue streams. These combined actions will help organizations convert scientific advances into reliable, accessible immunization solutions.

A rigorous, multi-source research methodology integrating primary expert interviews, regulatory review, scientific literature synthesis, and scenario-based supply chain analysis

This research synthesized qualitative and quantitative inputs across scientific literature, regulatory guidance documents, industry disclosures, technical briefings, and interviews with subject-matter experts across the value chain. Evidence synthesis prioritized peer-reviewed studies on platform immunology and formulation science, regulatory guidelines relevant to biologicals and novel modalities, and operational documentation from manufacturing and distribution stakeholders to create a comprehensive perspective on technology, supply, and adoption trends.

In addition to secondary research, primary engagements included structured interviews with laboratory researchers, manufacturing leaders, regulatory affairs professionals, and farm-level practitioners to validate assumptions and surface practical adoption barriers. Triangulation techniques were used to reconcile differing viewpoints and to ensure that conclusions reflect both scientific plausibility and operational feasibility. Analytic methods emphasized thematic coding for qualitative inputs and scenario analysis for supply chain and policy impact assessment, thereby providing robust, actionable insights for decision-makers.

Concluding synthesis emphasizing technology convergence, supply resilience, and collaborative approaches as the foundations for future progress in porcine immunization

The porcine vaccine ecosystem is increasingly defined by the interplay of technological innovation, operational pragmatism, and evolving policy environments. Advances in platform technologies offer genuine opportunities to improve protection breadth and speed of response, but realizing those gains requires synchronized investment in manufacturing flexibility, regulatory strategy, and field delivery capabilities. In parallel, trade policy shifts and supply chain pressure underscore the importance of regional diversification and supplier qualification to protect continuity of supply and to manage cost exposure.

Going forward, stakeholders that combine platform agility with deep end-user engagement and resilient supply arrangements will be best positioned to convert scientific progress into measurable animal health outcomes. Cross-sector collaboration-spanning developers, service providers, regulators, and farm networks-will remain essential to accelerate responsible adoption and to ensure that innovations translate into sustainable improvements in disease control and farm productivity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Porcine Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
    • 8.1.1. Split Virus
    • 8.1.2. Subcellular
    • 8.1.3. Whole Virus
  • 8.2. Live Attenuated
    • 8.2.1. Heterologous
    • 8.2.2. Homologous
  • 8.3. MRNA
    • 8.3.1. Non Amplifying MRNA
    • 8.3.2. Self Amplifying MRNA
  • 8.4. Subunit
    • 8.4.1. Polysaccharide Subunit
    • 8.4.2. Protein Subunit
  • 8.5. Virus Vectored
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Poxvirus Vector

9. Porcine Vaccines Market, by Disease Indication

  • 9.1. Classical Swine Fever
  • 9.2. Erysipelas
  • 9.3. Porcine Reproductive And Respiratory Syndrome
  • 9.4. Swine Influenza

10. Porcine Vaccines Market, by End User

  • 10.1. Commercial Farm
  • 10.2. Research Institute
  • 10.3. Smallholder Farm
  • 10.4. Veterinary Hospital

11. Porcine Vaccines Market, by Route Of Administration

  • 11.1. Intradermal
  • 11.2. Intramuscular
  • 11.3. Intranasal
  • 11.4. Oral
  • 11.5. Subcutaneous

12. Porcine Vaccines Market, by Technology

  • 12.1. Conventional
    • 12.1.1. Attenuated Live
    • 12.1.2. Killed Whole
  • 12.2. DNA
  • 12.3. Recombinant
    • 12.3.1. Bacteria Expressed
    • 12.3.2. Insect Cell Expressed
    • 12.3.3. Yeast Expressed
  • 12.4. RNA
  • 12.5. VLP

13. Porcine Vaccines Market, by Dosage Form

  • 13.1. Emulsion
  • 13.2. Liquid
  • 13.3. Lyophilized

14. Porcine Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Porcine Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Porcine Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Porcine Vaccines Market

18. China Porcine Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bimeda Holdings PLC
  • 19.6. Boehringer Ingelheim International GmbH
  • 19.7. Ceva Sante Animale S.A.
  • 19.8. Chengdu Tianbang Biological Products Co., Ltd.
  • 19.9. Chopper Animal Health Co., Ltd.
  • 19.10. Elanco Animal Health Incorporated
  • 19.11. Hipra, S.A.
  • 19.12. Indian Immunologicals Ltd.
  • 19.13. Jinyu Bio-Technology Co., Ltd.
  • 19.14. Kyoritsu Seiyaku Corporation
  • 19.15. Merck & Co., Inc.
  • 19.16. Pharmgate Animal Health, LLC
  • 19.17. Phibro Animal Health Corporation
  • 19.18. Qilu Animal Health Products Co., Ltd.
  • 19.19. Vaxxinova International BV
  • 19.20. Venkateshwara Hatcheries Pvt. Ltd.
  • 19.21. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL PORCINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 269. GCC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 272. GCC PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 273. GCC PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 274. GCC PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 275. GCC PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 276. GCC PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GCC PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GCC PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 281. GCC PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 282. GCC PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 311. G7 PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 312. G7 PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 314. G7 PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 315. G7 PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 316. G7 PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 317. G7 PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 318. G7 PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 319. G7 PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. G7 PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. G7 PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. G7 PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 323. G7 PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 324. G7 PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 325. NATO PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 326. NATO PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 328. NATO PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 329. NATO PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 330. NATO PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 331. NATO PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 332. NATO PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 333. NATO PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. NATO PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. NATO PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. NATO PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 337. NATO PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 338. NATO PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 339. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED STATES PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED STATES PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED STATES PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED STATES PORCINE VACCINES MARKET SIZE,